Literature DB >> 10423218

Rational 'DOTS plus' for the control of MDR-TB.

M A Espinal1, C Dye, M Raviglione, A Kochi.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10423218

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  10 in total

Review 1.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

2.  Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.

Authors:  Anandi Martin; Juan Carlos Palomino; Françoise Portaels
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

3.  To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.

Authors:  Jennifer Furin; Helen Cox
Journal:  Clin Infect Dis       Date:  2017-10-01       Impact factor: 9.079

Review 4.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

5.  Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.

Authors:  Anandi Martin; Mirtha Camacho; Françoise Portaels; Juan Carlos Palomino
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.

Authors:  Timothy R Sterling; Harold P Lehmann; Thomas R Frieden
Journal:  BMJ       Date:  2003-03-15

7.  The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.

Authors:  Mohammad Reza Javadi; Bahareh Abtahi; Kheirollah Gholami; Behzad Safari Moghadam; Payam Tabarsi; Jamshid Salamzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

8.  Clinical Impact on Tuberculosis Treatment Outcomes of Discordance Between Molecular and Growth-Based Assays for Rifampin Resistance, California 2003-2013.

Authors:  Neha S Shah; S Y Grace Lin; Pennan M Barry; Yi-Ning Cheng; Gisela Schecter; Ed Desmond
Journal:  Open Forum Infect Dis       Date:  2016-08-24       Impact factor: 3.835

9.  Genetic evaluation of relationship between mutations in rpoB and resistance of Mycobacterium tuberculosis to rifampin.

Authors:  Anna Zaczek; Anna Brzostek; Ewa Augustynowicz-Kopec; Zofia Zwolska; Jaroslaw Dziadek
Journal:  BMC Microbiol       Date:  2009-01-15       Impact factor: 3.605

10.  Tuberculosis-related deaths within a well-functioning DOTS control program.

Authors:  Maria De Lourdes García-García; Alfredo Ponce-De-León; Maria Cecilia García-Sancho; Leticia Ferreyra-Reyes; Manuel Palacios-Martínez; Javier Fuentes; Midori Kato-Maeda; Miriam Bobadilla; Peter Small; José Sifuentes-Osornio
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.